1 Introduction GLP-1 agonists for obesity treatment have imposed a substantial cost burden on the U.S. healthcare system; in response, the Trump administration has negotiated with the two main manufacturers (Novo Nordisk and Eli Lilly) to lower prices significantly. Under their agreement, Medicare and Medicaid prices decrease to $245 per month with a $50 patient copay [1].
Neeti S. Kulkarni
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Neeti S.
Contact Neeti S., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack